临床外科杂志 ›› 2020, Vol. 28 ›› Issue (8): 793-797.doi: 10.3969/j.issn.1005-6483.2020.08.030

• • 上一篇    下一篇

晚期胆道系统恶性肿瘤的化疗及靶向治疗药物进展

  

  1. 430030 武汉,华中科技大学同济医学院附属同济医院肿瘤中心消化系统肿瘤科
  • 出版日期:2020-08-20 发布日期:2020-08-20
  • 通讯作者: 邱红,Email:tjqiuhong@163.com

Advances in chemotherapy and targeted therapy for advanced biliary system malignancies

  1. Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
  • Online:2020-08-20 Published:2020-08-20

摘要: 胆道系统恶性肿瘤发病率目前有增高趋势,晚期胆道系统恶性肿瘤姑息性化疗效果差,生存期短。白蛋白紫杉醇等新型化疗药物及三药联合化疗方案的探索性治疗提高了晚期胆道系统恶性肿瘤化疗效果。近二十年来,肿瘤基因组分析及分子生物学基础研究进展进一步阐明了其发病机制,且伴随新药研发的不断进步,针对表皮生长因子受体家族靶点、抗血管生成药物靶点、MEK抑制剂、IDH1/2抑制剂及成纤维细胞生长因子受体(FGFR)抑制剂等药物对胆管癌显示了具有一定前景的抗肿瘤活性,部分药物已经获得临床试验成功及适应证批准。化疗及靶向治疗的联合治疗也进行了较多探索。本文就近些年来晚期胆道系统恶性肿瘤的化疗、靶向治疗进展进行综述。

关键词: 胆道系统恶性肿瘤, 化疗, 分子靶向治疗

Abstract: The incidence of biliary tract cancer keeps increasing during the past years,the efficacy of palliative chemotherapy is poor and results the short overall survival period.The exploratory treatment of new chemotherapeutics such as albumin paclitaxel and three-drug combination chemotherapy has improved the chemotherapy effect of advanced biliary malignant tumors.In the past two decades,tumor genome analysis and the progress of molecular biology research clarified furtherly its pathogenesis,and with the continuous development of new drugs,those drugs such as  EGFR inhibitors,anti-angiogenesis inhibitors,MEK inhibitors,IDH1 /2 inhibitors and FGFR inhibitors have shown promising anti-tumor merit against cholangiocarcinoma.Some drugs have been approved for indications.The combination of chemotherapy and targeted therapy has also been explored.This article reviews the progress of chemotherapy and molecular targeting therapy for advanced biliary tract cancer in recent years.

Key words: biliary tract cancer, chemotherapy, molecular targeting therapy

[1] 邓宇 郝博 耿庆. 小细胞肺癌治疗现状及展望[J]. 临床外科杂志, 2020, 28(7): 696-699.
[2] 韩加刚, 王振军. 梗阻性左半结肠癌治疗新策略-支架扩张联合新辅助化疗[J]. 临床外科杂志, 2020, 28(5): 401-403.
[3] 吴川清, 李源, 王点石, 杜周元, 吴轲, 高金波, 王征, 王国斌, 陶凯雄. 腹腔热灌注化疗治疗胃癌腹膜转移的安全性及有效性单中心临床研究[J]. 临床外科杂志, 2020, 28(5): 424-428.
[4] 狄子杨, 唐强, 狄茂军等. 腹腔热灌注化疗治疗晚期结直肠癌的疗效分析[J]. 临床外科杂志, 2020, 28(5): 433-436.
[5] 曾国祥, 黄修仿 . 腹腔镜微创根治术联合术中腹腔热灌注化疗对老年大肠癌病人血清TGF-β1及Periostin水平的影响[J]. 临床外科杂志, 2020, 28(2): 177-179.
[6] 夏雨佳, 左维维, 王梦园, 胡明. 亚甲基蓝在胃肠道恶性肿瘤淋巴结检获中应用价值的Meta分析[J]. 临床外科杂志, 2020, 28(1): 59-62.
[7] 严峻, 柏淳, 李锋, 傅文喜, 余小红. 经皮肝动脉化疗栓塞术联合索拉非尼治疗肝癌的疗效及安全性观察[J]. 临床外科杂志, 2019, 27(8): 668-670.
[8] 关树斌, 谷志涛, 茅腾等. 胸腺肿瘤淋巴结转移研究进展[J]. 临床外科杂志, 2019, 27(7): 622-625.
[9] 郑浩, 张仁泉. 局部进展期食管癌新辅助治疗的研究现状[J]. 临床外科杂志, 2019, 27(7): 626-629.
[10] 杨肖军, 熊斌. 腹腔热灌注化疗在胃肠道恶性肿瘤腹膜转移中的应用[J]. 临床外科杂志, 2019, 27(5): 443-445.
[11] 王璇, 张昊, 党诚学. 食管胃结合部肿瘤的治疗[J]. 临床外科杂志, 2019, 27(5): 446-448.
[12] 范威, 吴新红. 乳腺癌新辅助化疗后手术时机的选择[J]. 临床外科杂志, 2019, 27(3): 183-186.
[13] 马晓霞, 孙静岚, 郝楠, 刘小娜, 王霞, 葛冠群. 自我强化管理教育对中心静脉导管化疗乳腺癌病人自我带管管理能力的影响[J]. 临床外科杂志, 2019, 27(3): 209-212.
[14] 黄海涛, 王振军. 细胞减灭术和腹腔内热灌注化疗在结直肠癌腹膜转移的应用研究进展[J]. 临床外科杂志, 2019, 27(11): 1011-1013.
[15] 陶俊 王贵和. 局部进展期直肠癌新辅助放化疗后病理完全缓解的预测因素分析[J]. 临床外科杂志, 2018, 26(10): 756-759.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!